secwatch / observer
8-K filed March 15, 2023, 7:59 PM ET CIK 0001634379
M&A confidence high sentiment neutral materiality 0.50

Metacrine, Inc.: M&A transaction — Metacrine sells FXR program to Organovo for $4M cash

Metacrine, Inc.

item 1.01item 2.01

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

Metacrine, Inc. completed a disposition involving Organovo, Inc. for $2.0 million in cash (closed 2023-03-10).

Action
disposition
Counterparty
Organovo, Inc.
Consideration
$2.0 million in cash
Closing
2023-03-10
Exact text from the filing
property rights relating to its FXR program. As consideration for the Assets, under the terms of the Asset Agreement, Purchaser paid the Company an upfront payment of $2.0 million in cash and agreed to make an additional payment of $2.0 million in cash within five business days of the Company’s delivery of certain assets sold pursuant to the Asset
View on SEC.gov
Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Metacrine, Inc. entered into Asset Agreement with Organovo, Inc. valued at $2.0 million (effective 2023-03-10).

Action
entry
Agreement
asset purchase
Counterparty
Organovo, Inc.
Value
$2.0 million
Effective
2023-03-10
Exact text from the filing
On March 10, 2023, Metacrine, Inc. (the “Company”) entered into and closed the transactions contemplated by that certain Asset Purchase Agreement (the “Asset Agreement”) with Organovo, Inc. (“Purchaser”), pursuant to which the Company sold to Purchaser the right, title and interest in and to its farnesoid X receptor (“FXR”) program technology including all inventory, trial data and research records relating to its FXR program (collectively, the “Assets”).
View on SEC.gov

Browse all m&a transactions →

Source: SEC EDGAR
accession 0001193125-23-071470
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.